The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000692336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/04/2026
Date registered
Help: Date registered
10/06/2026
Date last updated
Help: Date last updated
10/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Sleep Apnoea Monitoring and Maximising Adherence Trial
Scientific title
Impact of a novel home monitoring and integrated support program on residual severity of obstructive sleep apnea symptoms
Additional trial identifiers [1] 316622 0
MRFF: 2035768
Universal Trial Number (UTN)
Trial acronym
SAMMA
Related trial records

Health condition
Health condition(s) studied:
Obstructive Sleep Apnoea 340824 0
Condition category
Condition code
Respiratory 336986 336986 0 0
Sleep apnoea

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants in the support arm will receive a multi-component support program in addition to standard CPAP care. The program comprises feedback about their measured sleep and breathing, educational and motivational materials, and access to trained support personnel, primarily delivered through the CareMappr app. The specific components have been and will continue to be developed in partnership with our consumer team, some of whom contributed to the initial conception of this work. The frequency of in-app prompts and the type of supports delivered will be flexible, enabling personalised support for each participant in the intervention arm.
Sleep and breathing data captured by the Withings under-mattress sensor will be transferred automatically to the CareMappr app via an established API integration between the two platforms; no manual data entry by participants or study staff is required. Participants will also be asked to complete brief in-app check-ins (daily for the first 14 days, then at a frequency selected by the individual) which provide self-reported data on CPAP use, symptoms, and sleep.
Educational materials presented within the app will include short-form videos co-developed with consumers and sleep clinicians, and written explainers and infographics covering topics such as CPAP mask fit, sleep hygiene, and managing common side effects. These will link to further information provided by partnering not-for-profit organisations (Australasian Sleep Association, Sleep Disorders Australia, Sleep Health Foundation). Motivational materials will include peer-experience video content, prompted and passive progress feedback drawn from the participant's own sleep data, and push notifications timed to support engagement at clinically relevant points (e.g., the first two weeks of therapy initiation).
Participants will be able to contact trained support personnel through an in-app embedded booking system. The support personnel are members of the study team (not CareMappr employees) with backgrounds in sleep health and CPAP support, who have also completed a bespoke, formal CPAP coaching program delivered remotely by inHealth Medical Services (California). Their role is to: troubleshoot device and app issues; respond to participant questions about therapy; provide brief, structured support drawn from the program's content modules; and identify and refer participants to their treating clinician or other appropriate services where clinical concerns are raised. Support personnel do not provide medical advice or alter prescribed therapy.
Usage or adherence of the intervention will be monitored using CareMappr app analytics, including frequency of app logins, time spent in educational content, completion of check-ins, and push notification delivery, open, and action rates. CPAP use will be captured separately via the device's standard data download. Where alternate treatments are initiated, adherence data will be collected via patient report in follow-up surveys and via clinical notes captured at follow-up clinical appointments. These metrics support program responsiveness for individual participants and will inform process evaluation but are not themselves trial outcomes.

Participants in both arms will continue with their usual clinical care, independent of the study intervention. This refers to ongoing management of OSA and any comorbid conditions by the participant's treating sleep physician, GP, and other clinicians as relevant, including attendance at scheduled appointments, prescribed CPAP follow-up, and any other directed management (e.g., weight management, positional therapy). The study does not alter or replace any element of routine clinical care.
During the 12-month monitoring period, participants in both arms will be given the Withings under-mattress sensor to monitor sleep and breathing, which will inform the primary outcome. All participants will also be offered optional access to the Hoap app - a smartphone-based daily check-in tool that records self-reported details about sleep timing and quality, mood, and daytime symptoms such as fatigue - as well as an finger-worn oximeter or a sleep tracking ring. These additional measurement tools are not part of the support program intervention. Participants will complete follow-up surveys remotely via REDCap at 3, 6, 9, and 12 months.
Intervention code [1] 333305 0
Treatment: Other
Intervention code [2] 334081 0
Treatment: Devices
Description of the comparator or control
Participants in the control arm will, like those in the intervention arm, have agreed to initiate CPAP therapy with their treating physician prior to enrolment. Participants are not required to remain on CPAP and may pursue alternative treatments (e.g., a mandibular advancement device) at any time, as directed by their treating clinician and without input from the study team.
During the 12-month monitoring period, participants in the control arm will be given the Withings under-mattress sensor to monitor sleep and breathing, but will not have access to this data. In addition, all participants (including those in the control arm) will be offered consumer sleep-related monitoring devices (e.g., access to the Hoap app, a pulse oximeter, and/or a sleep-tracking ring). Participants may elect to use or not use these devices without affecting study participation. Where utilised, data generated by these devices will be available to participants through their respective applications. Participants in the control arm will otherwise undergo usual treatment and management of their OSA.
All participants will also be asked to complete follow up surveys remotely via secure electronic forms. Participants will undergo follow-up at 3, 6, 9 and 12 months after their recruitment. Follow-up assessments will include standard sleep and health questionnaires, which will be captured remotely via REDCap.
Control group
Active

Outcomes
Primary outcome [1] 344518 0
Residual apnoea-hypopnea index (rAHI)
Timepoint [1] 344518 0
The final 90 days of nightly rAHI data available within the 12-month follow-up period. For participants with complete data, this corresponds to days 276–365 post-recruitment; where data are not available through to 12 months (e.g., due to discontinuation of device use), the last 90 days of available nightly rAHI data will be used, and the corresponding time period reported.
Primary outcome [2] 344519 0
Health related quality of life
Timepoint [2] 344519 0
Baseline, 3, 6, 9, and 12 months (primary timepoint) after recruitment
Secondary outcome [1] 458131 0
Therapy adherence - self report
Timepoint [1] 458131 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [2] 458132 0
Therapy adherence - objective
Timepoint [2] 458132 0
Nightly from therapy initiation until 12 months after recruitment.
Secondary outcome [3] 458133 0
Clinical observations and management details for OSA
Timepoint [3] 458133 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [4] 458134 0
Objective apnea-hypopnea index - PSG
Timepoint [4] 458134 0
At any scheduled follow-up appointments within the study period (up to 12-months post recruitment).
Secondary outcome [5] 458135 0
CPAP supply and equipment details
Timepoint [5] 458135 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [6] 458136 0
Implementation outcomes: reported acceptability
Timepoint [6] 458136 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [7] 458137 0
Implementation outcomes: appropriateness
Timepoint [7] 458137 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [8] 458138 0
Implementation outcomes: feasibility
Timepoint [8] 458138 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [9] 458139 0
Daytime sleepiness
Timepoint [9] 458139 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [10] 458143 0
Insomnia symptom severity
Timepoint [10] 458143 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [11] 458144 0
Functional impact of sleepiness on daily activities
Timepoint [11] 458144 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [12] 458145 0
Depression, anxiety and stress symptoms
Timepoint [12] 458145 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [13] 458374 0
Anxiety symptom severity
Timepoint [13] 458374 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [14] 458375 0
Sleep-related impairment
Timepoint [14] 458375 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [15] 458376 0
Sleep disturbance
Timepoint [15] 458376 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [16] 458378 0
Snoring severity (participant-rated and bed-partner rated where possible)
Timepoint [16] 458378 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [17] 458380 0
Self-reported alertness and safety outcomes
Timepoint [17] 458380 0
Baseline, 3, 6, 9 and 12 months after recruitment
Secondary outcome [18] 458383 0
Participant engagement with the personalised support program
Timepoint [18] 458383 0
12 months after recruitment at study completion.
Secondary outcome [19] 458384 0
Healthcare utilisation - MBS/PBS/AR-DRG
Timepoint [19] 458384 0
12 months after recruitment.
Secondary outcome [20] 461625 0
Acceptability of the support program intervention
Timepoint [20] 461625 0
3, 6, 9, and 12 months after recruitment.
Secondary outcome [21] 461626 0
Appropriateness of the support program intervention
Timepoint [21] 461626 0
3, 6, 9, and 12 months after recruitment.
Secondary outcome [22] 461627 0
Feasibility of the support program intervention
Timepoint [22] 461627 0
3, 6, 9, and 12 months after recruitment.
Secondary outcome [23] 461628 0
Clinician engagement with the personalised support program
Timepoint [23] 461628 0
From 12 months after the commencement of participant recruitment, until study completion.
Secondary outcome [24] 461629 0
Healthcare costs
Timepoint [24] 461629 0
12 months after recruitment.
Secondary outcome [25] 461874 0
Changes in OSA diagnosis
Timepoint [25] 461874 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [26] 461875 0
Changes in OSA treatment (e.g., pressure adjustments, mask changes, switches to alternative treatments)
Timepoint [26] 461875 0
3, 6, 9 and 12 months after recruitment
Secondary outcome [27] 461876 0
Objective sleep duration - PSG
Timepoint [27] 461876 0
At any scheduled follow-up appointments within the study period (up to 12-months post recruitment).
Secondary outcome [28] 461877 0
Objective sleep efficiency - PSG
Timepoint [28] 461877 0
At any scheduled follow-up appointments within the study period (up to 12-months post recruitment).
Secondary outcome [29] 461878 0
Objective sleep architecture - PSG
Timepoint [29] 461878 0
At any scheduled follow-up appointments within the study period (up to 12-months post recruitment).
Secondary outcome [30] 461879 0
Objective arousal indices - PSG
Timepoint [30] 461879 0
At any scheduled follow-up appointments within the study period (up to 12-months post recruitment).
Secondary outcome [31] 461880 0
Objective oxygen desaturation - PSG
Timepoint [31] 461880 0
At any scheduled follow-up appointments within the study period (up to 12-months post recruitment).
Secondary outcome [32] 461883 0
Healthcare utilisation - resource use questionnaire
Timepoint [32] 461883 0
12 months after recruitment.

Eligibility
Key inclusion criteria
1. Adult aged 18 years or over
2. Positive diagnosis of OSA by their treating physician
3. CPAP indicated as first-line treatment by treating physician
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Inability or unwillingness to provide informed consent
2. Unwillingness to undergo CPAP treatment for their OSA

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealed via central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Minimisation randomisation based on age, sex, BMI, recruitment site, and referring/treating physician.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Differences between arms in both residual AHI and EQ-5D-5L VAS at 12 months will be evaluated using linear regression with arm and initial baseline values as predictors. Crosswalk mapping will be employed to derive an EQ-5D index, which will also be analysed using linear regression with arm and initial baseline values as predictors. If linear regression assumptions fail, due to the distribution of EQ-5D value data, other models including Tobit, censored least absolute deviation, other median models, two-part models, latent-class models, and limited dependent variable mixture models will be considered.

A model-based economic evaluation will compare home monitoring sleep vs. usual care. The model will assess both short-term (12-month trial-based) and long-term (beyond-trial) costs and outcomes. Short-term data comes from the trial, while long-term data will be gathered through a literature review. The primary economic evaluation outcome will be based on a cost-utility analysis (CUA) that will report incremental costs per quality-adjusted life year (QALY) gained, calculated using EQ-5D-5L data and survival curves. The secondary economic evaluation will report incremental costs per unit change in the rAHI. Incremental costs for all pathways will include GP visits, referrals, medication, and intervention implementation (training, resources, etc.). Costs will be drawn from MBS/PBS/AR-DRG data and the literature review. Uncertainty will be addressed through bootstrapping, informing decision-makers about the optimal strategy for different subgroups and thresholds, considering cost-effectiveness, acceptability, net benefit, and uncertainty.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 29204 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 29205 0
Woolcock Institute of Medical Research - Glebe
Recruitment postcode(s) [1] 45513 0
5042 - Bedford Park
Recruitment postcode(s) [2] 45514 0
2037 - Glebe

Funding & Sponsors
Funding source category [1] 320608 0
Government body
Name [1] 320608 0
Australian Department of Health, Disability and Ageing, Medical Research Future Fund (MRFF)
Country [1] 320608 0
Australia
Primary sponsor type
University
Name
Flinders University
Address
Country
Australia
Secondary sponsor category [1] 324733 0
None
Name [1] 324733 0
Address [1] 324733 0
Country [1] 324733 0
Other collaborator category [1] 283939 0
Commercial sector/Industry
Name [1] 283939 0
Lumin/Hoap
Address [1] 283939 0
Country [1] 283939 0
Australia
Other collaborator category [2] 283940 0
Commercial sector/Industry
Name [2] 283940 0
Withings
Address [2] 283940 0
Country [2] 283940 0
France
Other collaborator category [3] 283941 0
Commercial sector/Industry
Name [3] 283941 0
CareMappr
Address [3] 283941 0
Country [3] 283941 0
Australia
Other collaborator category [4] 283942 0
Charities/Societies/Foundations
Name [4] 283942 0
Australasian Sleep Association (ASA)
Address [4] 283942 0
Country [4] 283942 0
Australia
Other collaborator category [5] 283943 0
Charities/Societies/Foundations
Name [5] 283943 0
Sleep Health Foundation (SHF)
Address [5] 283943 0
Country [5] 283943 0
Australia
Other collaborator category [6] 283945 0
Hospital
Name [6] 283945 0
Southern Adelaide Local Health Network (SALHN)
Address [6] 283945 0
Country [6] 283945 0
Australia
Other collaborator category [7] 283946 0
University
Name [7] 283946 0
Macquarie University
Address [7] 283946 0
Country [7] 283946 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319151 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [1] 319151 0
Ethics committee country [1] 319151 0
Australia
Date submitted for ethics approval [1] 319151 0
26/02/2026
Approval date [1] 319151 0
22/04/2026
Ethics approval number [1] 319151 0
2025/HRE00431

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 146418 0
Prof Robert Adams
Address 146418 0
Adelaide Institute for Sleep Health, Level 2A, 5 Laffer Drive, Bedford Park, 5042, SA, Australia
Country 146418 0
Australia
Phone 146418 0
+61 8 7421 9751
Fax 146418 0
Email 146418 0
Contact person for public queries
Name 146419 0
Robert Adams
Address 146419 0
Adelaide Institute for Sleep Health, Level 2A, 5 Laffer Drive, Bedford Park, 5042, SA, Australia
Country 146419 0
Australia
Phone 146419 0
+61 8 7421 9751
Fax 146419 0
Email 146419 0
Contact person for scientific queries
Name 146420 0
Robert Adams
Address 146420 0
Adelaide Institute for Sleep Health, Level 2A, 5 Laffer Drive, Bedford Park, 5042, SA, Australia
Country 146420 0
Australia
Phone 146420 0
+61 8 7421 9751
Fax 146420 0
Email 146420 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.